Chardan Capital analyst Matthew Barcus reiterated a Buy rating on Xilio Therapeutics (XLO – Research Report) today and set a price target of $7.00. The company’s shares closed last Friday at $3.06.
Barcus covers the Healthcare sector, focusing on stocks such as uniQure, Anixa Biosciences, and Xilio Therapeutics. According to TipRanks, Barcus has an average return of 1.3% and a 27.78% success rate on recommended stocks.
Xilio Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $8.50.
See the top stocks recommended by analysts >>
Based on Xilio Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $22.65 million. In comparison, last year the company had a GAAP net loss of $21.35 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer.
Read More on XLO:
- Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors
- Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results
- Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
